NCT06570798

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-07-16Est. Completion: 2028-08-06

Enrollment target: 220 participants

Locations

HonorHealth Research and Innovation Institute, Scottsdale, Arizona, United States
University of Colorado, Aurora, Colorado, United States
Vida Research Center, Hialeah, Florida, United States
Homestead Associates In Research Inc, Homestead, Florida, United States
Vitaly Clinical Research, Miami, Florida, United States
Bioresearch Partner Coral Terrace, South Miami, Florida, United States
University Medical Center New Orleans, New Orleans, Louisiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
Northwell Health, Great Neck, New York, United States
Westchester Medical Center, Hawthorne, New York, United States
Columbia University Medical Center, New York, New York, United States
University of Rochester Medical Center, Rochester, New York, United States
MetroHealth Medical Center, Cleveland, Ohio, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Prolato Clinical Research Center, Houston, Texas, United States

Autoimmune Diseases

Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…

Bethesda, United StatesEst. completion Apr 22, 2030

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary HypertensionOther Autoimmune Diseases (AID)

This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (…

Beijing, ChinaEst. completion Jul 31, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.